Provided by Tiger Trade Technology Pte. Ltd.

Celldex Therapeutics

36.90
-1.2000-3.15%
Post-market: 36.38-0.5200-1.41%17:08 EDT
Volume:1.03M
Turnover:38.64M
Market Cap:2.90B
PE:-8.50
High:38.59
Open:38.39
Low:36.84
Close:38.10
52wk High:45.14
52wk Low:22.10
Shares:78.49M
Float Shares:73.02M
Volume Ratio:1.61
T/O Rate:1.42%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.3401
EPS(LYR):-3.9000
ROE:-43.88%
ROA:-27.62%
PB:4.05
PE(LYR):-9.46

Loading ...

Analysts Are Bullish on Top Healthcare Stocks: Vanda (VNDA), Celldex (CLDX)

TIPRANKS
·
Jul 22

Celldex price target lowered to $61 from $67 at Cantor Fitzgerald

TIPRANKS
·
Jul 22

Celldex Therapeutics is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Jul 22

Wells Fargo Keeps Their Buy Rating on Celldex (CLDX)

TIPRANKS
·
Jul 22

Celldex Therapeutics Inc : Morgan Stanley Cuts Target Price to $40.00 from $44.00

THOMSON REUTERS
·
Jul 22

Analysts Offer Insights on Healthcare Companies: Celldex (CLDX), Bristol-Myers Squibb (BMY) and Peptidream (OtherPPTDF)

TIPRANKS
·
Jul 22

Celldex Therapeutics Inc : Leerink Partners Cuts Target Price to $70 from $78

THOMSON REUTERS
·
Jul 22

Morgan Stanley Adjusts PT on Celldex Therapeutics to $40 From $44, Maintains Overweight Rating

MT Newswires Live
·
Jul 22

U.s. Research Roundup-danaher, Gm, Msci

Reuters
·
Jul 22

Celldex Shares Fall After it Drops Skin Disease Drug Study

Reuters
·
Jul 22

Celldex to End Phase 2 Study for Skin-disease Treatment

Dow Jones
·
Jul 22

Celldex reports barzolvolimab study did not meet primary, secondary endpoints

TIPRANKS
·
Jul 22

Celldex Posts Press Release on Phase 2 Barzolvolimab Results in Prurigo Nodularis

Reuters
·
Jul 22

Celldex Therapeutics - Profound Systemic Mast Cell Depletion Observed in Phase 2 Study

THOMSON REUTERS
·
Jul 22

Celldex Therapeutics Inc: Favorable Safety Profile Consistent with Prior Studies, Including with New 450mg Loading Dose and up to 300mgq4w Regimen

THOMSON REUTERS
·
Jul 22

Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis

THOMSON REUTERS
·
Jul 22

Celldex Therapeutics - Phase 3 Csu Topline Data Expected Sept/oct 2026; Phase 3 Sd and Coldu Enrollment on Track

THOMSON REUTERS
·
Jul 22

Celldex Therapeutics is Maintained at Buy by Guggenheim

Dow Jones
·
Jul 20

Celldex price target raised to $100 from $90 at Guggenheim

TIPRANKS
·
Jul 20

Celldex Initiates Search for New CFO Ahead of Martin's Retirement

Dow Jones
·
Jul 16